Rivastigmine Patch
Product Images NDC 65162-825

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Rivastigmine (NDC 65162-825). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chem Structure (Rivastigmine Transdermal System 1)

Chemical structure of Rivastigmine, showing its molecular components including aromatic rings, methyl groups, and carbamate moiety as depicted in the diagram.*

FDA Label Image

Figure A- New (Rivastigmine Transdermal System 10)

Illustration showing the packaging and components of the Rivastigmine transdermal patch 4.6 mg/24 hours by Amneal Pharmaceuticals. It depicts the pouch containing the patch, the patch labeled with the active ingredient and strength, and the adhesive side with protective liners and outside backing labeled.*

FDA Label Image

Figure B (Rivastigmine Transdermal System 11)

Illustration showing possible application sites for a transdermal patch on a human male figure. Sites are labeled for left or right upper arm (side view), left or right side of chest (front and back view), left or right upper back (back view), and left or right lower back (back view). Each site is marked with a shaded square area indicating patch placement.*

FDA Label Image

Figure C- New (Rivastigmine Transdermal System 12)

An instructional illustration showing a hand holding a Rivastigmine Transdermal System package while scissors cut it open along a dotted line. The package is labeled with the product name, usage instructions for transdermal application, and the Amneal Pharmaceuticals LLC logo at the bottom.*

FDA Label Image

Figure D (Rivastigmine Transdermal System 13)

An instructional illustration showing the removal of protective liners from the sticky surface of a Rivastigmine transdermal patch. The image depicts fingers peeling away two protective liners to expose the adhesive side of the patch for application.*

FDA Label Image

Figure E (Rivastigmine Transdermal System 14)

An instructional illustration showing a person applying a Rivastigmine transdermal patch to the upper back just below the neck, demonstrating proper placement and application technique for the patch.*

FDA Label Image

Figure F (Rivastigmine Transdermal System 15)

An instructional illustration showing a hand placing a transdermal patch on the upper back of a person's body. The image depicts proper patch application location, focusing on the upper shoulder area of the back for a patch like Rivastigmine transdermal.*

FDA Label Image

Figure G (Rivastigmine Transdermal System 16)

An instructional illustration showing the application of a transdermal patch to the upper back. A person is peeling off the backing of the patch with one hand while placing it on the skin with the other, demonstrating the correct method of applying a patch to the body.*

FDA Label Image

Figure H- New (Rivastigmine Transdermal System 17)

An instructional illustration showing three steps for disposing of a Rivastigmine transdermal patch. The first panel demonstrates folding the sticky sides of the patch together. The second panel shows sliding the folded patch into its original empty pouch. The third panel depicts placing the pouch into a trash bin, with a reminder to keep discarded patches away from children and pets.*

FDA Label Image

4.6 Pouch (Rivastigmine Transdermal System 18)

Rivastigmine Transdermal System patch packaging from Amneal Pharmaceuticals LLC, delivering 4.6 mg per 24 hours. The front of the pouch is labeled for transdermal use only and indicates it contains one system. The back includes application instructions, storage conditions, and distributor information from Amneal Pharmaceuticals in Bridgewater, NJ.*

FDA Label Image

4.6 Carton (Rivastigmine Transdermal System 19)

The image shows a flat layout of a packaging label for Rivastigmine Transdermal System, 4.6 mg/24 hours, produced by Amneal Pharmaceuticals LLC. The label states the box contains 30 patches, each delivering 4.6 mg of rivastigmine over 24 hours. Instructions for disposal, storage, and usage are included along with the NDC 65162-825-34 and distributor information. The design features the Amneal logo and safety warnings.*

FDA Label Image

Figure 1 (Rivastigmine Transdermal System 2)

A cross-sectional diagram illustrating the four layers of a Rivastigmine transdermal patch, highlighting structural details and the presence of dimples at the edges. The image depicts layer arrangement and key design features relevant to the patch's function.*

FDA Label Image

9.5 mg Pouch (Rivastigmine Transdermal System 20)

Packaging label of Rivastigmine Transdermal System patch delivering 9.5 mg/24 hours by Amneal Pharmaceuticals. The front pouch shows the product name, dosage strength, NDC number, and usage note for transdermal use only. The back pouch includes storage instructions, usage directions emphasizing wearing one patch at a time and not cutting the patch, and distributor information.*

FDA Label Image

9.5 Carton (Rivastigmine Transdermal System 21)

Packaging label for Rivastigmine Transdermal System 9.5 mg/24 hours patch by Amneal Pharmaceuticals LLC. The label states it contains 30 systems, each delivering 9.5 mg rivastigmine over 24 hours. It includes storage and safety instructions, lot number and expiration date areas, usage directions, and a barcode. The label is primarily white with beige and black text and an Amneal logo at the bottom.*

FDA Label Image

13.3 Pouch (Rivastigmine Transdermal System 22)

Rivastigmine Transdermal System patch delivering 13.3 mg/24 hours for transdermal use only. The pouch contains 1 system and is labeled for Rx only. The front includes lot and expiration date fields and Amneal Pharmaceuticals branding. The back provides application instructions, storage conditions, and distributor information for Amneal Pharmaceuticals in Bridgewater, NJ.*

FDA Label Image

13.3 Carton (Rivastigmine Transdermal System 23)

Packaging label for Rivastigmine Transdermal System 13.3 mg/24 hours by Amneal Pharmaceuticals LLC. The folded box contains 30 transdermal patches, each delivering 13.3 mg of rivastigmine over 24 hours. The label includes disposal instructions, storage conditions, inactive ingredients, and a barcode. The design features black and orange text on a white background with the Amneal logo in orange at the bottom.*

FDA Label Image

Carton Inside (Rivastigmine Transdermal System 24)

An instructional illustration of the Rivastigmine transdermal system carton template showing folding and cutting lines. The panel includes step-by-step visual and textual instructions for applying the Rivastigmine patch to clean, dry, hairless skin on the back, upper arm, or chest, with warnings to use only one patch at a time and to remove previous patches before applying new ones.*

FDA Label Image

Figure 2 (Rivastigmine Transdermal System 3)

Line graph showing Rivastigmine plasma concentration (ng/mL) over 24 hours for three transdermal patch strengths: 13.3 mg/24h, 9.5 mg/24h, and 4.6 mg/24h. The graph includes error bars for each time point from 0 to 24 hours, illustrating mean concentration trends and variability for each dose group.*

FDA Label Image

Figure 3 (Rivastigmine Transdermal System 4)

A line graph showing clinical improvement and decline over 24 weeks of treatment with different Rivastigmine dosages and placebo. The x-axis indicates weeks during treatment (0, 16, 24) and the y-axis shows least square means change in ADAS-Cog rating. Four lines represent 17.4 mg/24 hours patch, 9.5 mg/24 hours patch, 6 mg BID capsules, and placebo, illustrating changes in scores over time with error bars.*

FDA Label Image

Figure 4 (Rivastigmine Transdermal System 5)

Bar chart depicting the percentage distribution of patients' responses on the ADCS-CGIC rating scale to Rivastigmine treatments and placebo. It compares 17.4 mg/24 hours and 9.5 mg/24 hours transdermal patches with 6 mg capsules BID and placebo across categories from markedly improved to markedly worse.*

FDA Label Image

Figure 5 (Rivastigmine Transdermal System 6)

A line graph comparing ADCS-ADL change from baseline over 48 weeks of treatment between Rivastigmine Transdermal System 13.3 mg/24 hr and 9.5 mg/24 hr. The x-axis represents weeks of treatment from 0 to 52, and the y-axis represents change from baseline with a scale from -8 to 4. The graph shows clinical improvement upwards and clinical decline downwards. Data points for both doses are plotted with error bars, with the 13.3 mg/24 hr dose generally showing less decline than the 9.5 mg/24 hr dose over time. Significant differences (p<0.05) between the two doses are marked with an "x."*

FDA Label Image

Figure 6 (Rivastigmine Transdermal System 7)

A line graph depicting ADAS-Cog change from baseline over weeks of treatment for Rivastigmine Transdermal System patches at 13.3 mg/24 hr and 9.5 mg/24 hr doses. The vertical axis shows clinical improvement to decline, and the horizontal axis shows weeks up to 48. The 13.3 mg dose shows less cognitive decline than the 9.5 mg dose, with statistical significance noted at 24 weeks.*

FDA Label Image

Figure 7 (Rivastigmine Transdermal System 8)

A line graph comparing the least squares mean change over 24 weeks of treatment between Rivastigmine patch 13.3 mg/24 hr and Rivastigmine patch 4.6 mg/24 hr. The vertical axis shows LS mean change with standard errors, and the horizontal axis shows weeks of treatment. The graph indicates clinical improvement with the 13.3 mg/24 hr patch, unlike the 4.6 mg/24 hr patch which shows clinical decline over time.*

FDA Label Image

Figure 8 (Rivastigmine Transdermal System 9)

A line graph showing least squares mean changes over 24 weeks of treatment comparing Rivastigmine patches at 3.3 mg/24h and 4.6 mg/24h. The x-axis represents weeks of treatment, and the y-axis represents LS mean change with standard error. Statistical significance values are noted at weeks 16 and 24, indicating clinical improvement or decline.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.